Published in AIDS Weekly, August 4th, 2003
In a recent study from Sweden, "the kinetics of the interaction between drug-resistant variants of HIV-1 protease (G48V, V82A, L90M, 184V/L90M, and G48V/V82A/I84V/L90M) and clinically used inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) were determined using biosensor technology."
"The enzyme variants were immobilized on a biosensor chip and the association and dissociation rate constants (k(on) and k(off)) and affinities (K-D) for interactions with inhibitors" were measured by C.F. Shuman and colleagues at the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.